AbbVie secures EC approval for Skyrizi to treat active Crohn’s disease
Skyrizi is a humanised monoclonal antibody inhibitor that selectively targets interleukin-23 (IL-23), a cytokine involved in inflammatory processes,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
24 Nov 22
Skyrizi is a humanised monoclonal antibody inhibitor that selectively targets interleukin-23 (IL-23), a cytokine involved in inflammatory processes,…
23 Nov 22
Hemgenix is a gene therapy that promotes continuous production of factor IX to reduce abnormal bleeding in people…
22 Nov 22
Merck, through its acquisition subsidiary, will initiate a tender offer to acquire all outstanding shares of Imago for…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Nov 22
The expanded approval adds new dosing options for Rylaze, which provides sustained asparaginase activity for adult and paediatric…
18 Nov 22
TZIELD is an anti-CD3-directed antibody, indicated for administration as a once-daily intravenous infusion for 14 days, to delay…
17 Nov 22
Zolbetuximab is an investigational monoclonal antibody that targets Claudin 18.2 and is used for the treatment of CLDN18.2-positive,…
16 Nov 22
"Whether elevating special gatherings like holiday parties or gifting moments with family and friends, Ferrero Rocher is the…
16 Nov 22
To determine which foods should be included on the FTL, the FDA developed a risk-ranking model for food…
15 Nov 22
The company will initiate a post-approval efficacy study in areas with active chikungunya virus (CHIKV) transmission, in collaboration…
14 Nov 22
The FDA approval is supported by positive results from the Phase 3 POSEIDON study, which showed a significant…